Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial ResultsBusiness Wire · 3 days ago
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?Zacks Investment Research · 5 days ago
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness MonthZacks Investment Research · Oct 16, 2026
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)Business Wire · Oct 5, 2026
Comparing TG Therapeutics (NASDAQ:TGTX) and Puma Biotechnology (NASDAQ:PBYI)Defense World · Sep 26, 2026
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer BeginsZacks Investment Research · Sep 18, 2026Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | $0.04 | $0.19 | Beat |
| May 7, 2026 | -$0.13 | -$0.04 | Beat |
| Feb 26, 2026 | $0.24 | $0.29 | Beat |
| Nov 6, 2025 | $0.09 | $0.21 | Beat |
| Aug 7, 2025 | $0.11 | $0.15 | Beat |
| May 8, 2025 | $0.02 | $0.10 | Beat |